Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; IHD, ischemic heart disease; PAF, population attributable fraction; TIA, transient ischemic attack. * For the number of antihypertensive medications use, first, we calculated the total days of antihypertensive medications coverage for beneficiaries who took one, two, three or more medications during the period of follow-up respectively, and second, we classified the beneficiaries into one, and two or more medications use groups if he/she took one, or two or more medications for ≥75% of days during the follow-up. The beneficiaries who did not fall into the above defined one, or two or more medications use groups were excluded from this sensitivity analysis. † P-value for trends across the categories of proportion days covered; all tests two-tailed. ‡ PAF adjusted for age, sex, race/ethnicity, urban-rural residence, statins use, number of antihypertensive medications, status of low-income subsidy, out of pocket medications payment/day, Charlson-Comorbidity-Index, and 10 chronic conditions at baseline. § CVD events included both fatal and non-fatal events, and numbers in parentheses indicate the nonfatal events. || Adjusted for age, sex, race/ethnicity, urban-rural residence, statins use, number of antihypertensive medications, status of low-income subsidy, out of pocket medications payment/day, CharlsonComorbidity-Index, and 10 chronic conditions at baseline. * We calculated the interval-based cumulative PDC of one or more (≥1) antihypertensives on hand during the first year of follow-up or follow-up to the first fatal or nonfatal CVD events for the beneficiaries who had a CVD event within first year of follow-up using information in Medicare Part D drug claim data. † P-value for trends across the categories of proportion days covered; all tests two-tailed. ‡ PAF adjusted for age, sex, race/ethnicity, urban-rural residence, statins use, number of antihypertensive medications, status of low-income subsidy, out of pocket medications payment/day, Charlson-Comorbidity-Index, and 10 chronic conditions at baseline. § CVD events included both fatal and non-fatal events, and numbers in parentheses indicate the nonfatal events. || Adjusted for age, sex, race/ethnicity, urban-rural residence, statins use, number of antihypertensive medications, status of low-income subsidy, out of pocket medications payment/day, CharlsonComorbidity-Index, and 10 chronic conditions at baseline. For the dose-response analyses of relationship between average PDC and CVD events, we used the 20th percentile PDC as the referent value (mid-value among beneficiaries with <40% PDC).
